Nuvectis Pharma (NASDAQ: NVCT) net income
Nuvectis Pharma reported a net loss of $26.4m for fiscal 2025; in fiscal 2024 it reported a net loss of $19.0m. Earnings per share were −$1.32.
Nuvectis Pharma's best year of the last 5 was fiscal 2021. It reported a loss in 5 of those 5 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$26.4m | — | — | −$1.32 |
| 2024 | −$19.0m | — | — | −$1.11 |
| 2023 | −$22.3m | — | — | −$1.43 |
| 2022 | −$19.1m | — | — | −$1.51 |
| 2021 | −$12.9m | — | — | −$3.02 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Nuvectis Pharma net income compared with its sector
By net income for its latest fiscal year, Nuvectis Pharma ranks 219th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 217th | ClearPoint Neuro | −$25.5m | −69.1% |
| 218th | Travere Therapeutics | −$25.5m | −5.2% |
| 219th | Nuvectis Pharma | −$26.4m | — |
| 220th | Unicycive Therapeutics | −$26.6m | — |
| 221st | SELLAS Life Sciences Group | −$26.9m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Nuvectis Pharma
- How much did Nuvectis Pharma earn in fiscal 2025?
- Nuvectis Pharma reported a net loss of $26.4m for fiscal 2025. In fiscal 2024 it reported a net loss of $19.0m.
- What are the earnings per share of Nuvectis Pharma?
- They were −$1.32 in fiscal 2025, compared with −$1.11 in fiscal 2024.
- Where does Nuvectis Pharma rank in its sector by net income?
- It ranks 219th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Nuvectis Pharma come from?
- From the annual report (Form 10-K) that Nuvectis Pharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Nuvectis Pharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. More on Nuvectis Pharma: the Nuvectis Pharma page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.